
Mona Munteanu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9344197/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology, 2006, 6, 6.	0.8	378
2	Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages. Clinical Chemistry, 2007, 53, 1615-1622.	1.5	227
3	Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection. Gastroenterology, 2012, 143, 1244-1252.e12.	0.6	142
4	Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data. PLoS ONE, 2012, 7, e30325.	1.1	117
5	Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. BMC Gastroenterology, 2011, 11, 39.	0.8	58
6	Longâ€ŧerm prognostic value of the FibroTest in patients with nonâ€alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 1117-1127.	1.9	28
7	FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program. Journal of Hepatology, 2011, 54, 227-235.	1.8	19
8	Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. European Journal of Gastroenterology and Hepatology, 2018, 30, 569-577.	0.8	15
9	LCR1 and LCR2, two multiâ€analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Alimentary Pharmacology and Therapeutics, 2019, 49, 308-320.	1.9	15
10	Impact of steatosis and inflammation definitions on the performance of NASH tests. European Journal of Gastroenterology and Hepatology, 2018, 30, 384-391.	0.8	13
11	The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. European Journal of Gastroenterology and Hepatology, 2019, 31, 393-402.	0.8	12
12	Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. European Journal of Gastroenterology and Hepatology, 2020, 32, 998-1007.	0.8	8
13	Identification of an Endoglin Variant Associated With HCV-Related Liver Fibrosis Progression by Next-Generation Sequencing. Frontiers in Genetics, 2019, 10, 1024.	1.1	6
14	Consequences of Extended Spectrum Beta‣actamase–Producing Enterobacteriaceae and Methicillinâ€Resistant Staphylococcus aureus Carriage in Awaiting Liver Transplant Patients. Liver Transplantation, 2021, 27, 43-54.	1.3	5